A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase 1 study to determine the maximum tolerated dose (MTD) or
appropriate target dose if MTD not reached to identify the recommended phase 2 dose of
LOR-253 HCl in patients with advanced or metastatic solid tumours.